Schnitzler syndrome complete resolution of symptoms on treatment with anakinra after 12 years of unsuccessful therapy with other regimens

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F09%3A00037270" target="_blank" >RIV/00216224:14110/09:00037270 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Schnitzler syndrome complete resolution of symptoms on treatment with anakinra after 12 years of unsuccessful therapy with other regimens

Popis výsledku v původním jazyce

Schnitzler syndrome is a rare disorder characterized by chronic urticaria, the presence of monoclonal class IgM immunoglobulin, lymphadenopathy and fevers. We report on a patient who was diagnosed in 1996 and over the next 12 years underwent a number oftherapies. Bone pain associated with proven osteolytic and osteosclerotic lesions resolved on regular bisphosphonate treatment with pamidronate and, later, clodronate. The patient had transient benefit from treatments with interferon-alpha and with PUVA.No therapeutic effects were seen with high-dose dexamethasone, 2-chlordeoxyadenosin, cyclosporine, or the combination of bortezomib, thalidomide, and dexamethasone. However, on therapy with anakinra the patients skin symptoms resolved completely and thevalues of CRP and hemoglobin normalized.

Název v anglickém jazyce

Schnitzler syndrome complete resolution of symptoms on treatment with anakinra after 12 years of unsuccessful therapy with other regimens

Popis výsledku anglicky

Schnitzler syndrome is a rare disorder characterized by chronic urticaria, the presence of monoclonal class IgM immunoglobulin, lymphadenopathy and fevers. We report on a patient who was diagnosed in 1996 and over the next 12 years underwent a number oftherapies. Bone pain associated with proven osteolytic and osteosclerotic lesions resolved on regular bisphosphonate treatment with pamidronate and, later, clodronate. The patient had transient benefit from treatments with interferon-alpha and with PUVA.No therapeutic effects were seen with high-dose dexamethasone, 2-chlordeoxyadenosin, cyclosporine, or the combination of bortezomib, thalidomide, and dexamethasone. However, on therapy with anakinra the patients skin symptoms resolved completely and thevalues of CRP and hemoglobin normalized.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/LC06027" target="_blank" >LC06027: Univerzitní výzkumné centrum - Česká myelomová skupina</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2009

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cancer Therapy

ISSN

1543-9135

e-ISSN

—

Svazek periodika

7

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

6

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—